背景(考古学)
肌肉肥大
医学
毒性
生理学
不利影响
核受体
孕烷X受体
病理
生物
药理学
内科学
转录因子
生物化学
基因
古生物学
作者
A P Hall,C. R. Elcombe,J. R. Foster,Harada T,W Kaufmann,A. Knippel,K. Küttler,D. E. Malarkey,R. R. Maronpot,A. Nishikawa,T Nolte,A. Schulte,V. Strauss,M. J. York
标识
DOI:10.1177/0192623312448935
摘要
Preclinical toxicity studies have demonstrated that exposure of laboratory animals to liver enzyme inducers during preclinical safety assessment results in a signature of toxicological changes characterized by an increase in liver weight, hepatocellular hypertrophy, cell proliferation, and, frequently in long-term (life-time) studies, hepatocarcinogenesis. Recent advances over the last decade have revealed that for many xenobiotics, these changes may be induced through a common mechanism of action involving activation of the nuclear hormone receptors CAR, PXR, or PPARα. The generation of genetically engineered mice that express altered versions of these nuclear hormone receptors, together with other avenues of investigation, have now demonstrated that sensitivity to many of these effects is rodent-specific. These data are consistent with the available epidemiological and empirical human evidence and lend support to the scientific opinion that these changes have little relevance to man. The ESTP therefore convened an international panel of experts to debate the evidence in order to more clearly define for toxicologic pathologists what is considered adverse in the context of hepatocellular hypertrophy. The results of this workshop concluded that hepatomegaly as a consequence of hepatocellular hypertrophy without histologic or clinical pathology alterations indicative of liver toxicity was considered an adaptive and a non-adverse reaction. This conclusion should normally be reached by an integrative weight of evidence approach.
科研通智能强力驱动
Strongly Powered by AbleSci AI